Brief: Xuanzhu Biopharmaceutical Posts Full-Year Revenue Of RMB51.8 Million
30/03/2026 11:19
March 30 (Reuters) - Xuanzhu Biopharmaceutical Co Ltd 2575.HK: FY REVENUE RMB51.8 MILLION FY LOSS ATTRIBUTABLE RMB245.5 MILLION Further company coverage: 2575.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xuanzhu Biopharmaceutical
See all newsBrief: Xuanzhu Biopharmaceutical Announces Commercial Cooperation With Innobic For Birecociclib
Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology